OrthoPediatrics today priced its initial public offering at $13 per share, meaning the 4-million-share flotation pulled in $52 million for its line of surgical systems for children.
The offering includes a 30-day underwriters over-allotment of 600,000 extra shares, which if fully exercised would push the IPO’s total raise to $59.8 million.
Warsaw, Ind.-based OrthoPediatrics produces 21 surgical systems designed to support orthopedic trauma cases and said it has plans to expand its offerings into additional categories, including foot & ankle, hand & wrist, clavicle, pelvis and sports-related injuries.
Shares trading on the NASDAQ exchange under the “KIDS” symbol were up 45.6% to $18.91 in mid-day trading today.
The proceeds are earmarked for dealing out unpaid dividends the company’s Series B preferred stock, investing in implants and instrument sets for customer consignment and for R&D, sales expansion and general corporate purposes, the company said.
Piper Jaffray and Stifel, Nicolaus are acting as joint book-runners for the offering, which is set to close Oct. 16.
The company originally registered for an initial public offering worth $75 million in June, but modified the range to between $12 and $14 per share earlier this month.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.